XmAb 541
Alternative Names: XmAb-541Latest Information Update: 16 May 2024
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ovarian cancer; Solid tumours
Most Recent Events
- 04 Apr 2024 Phase-I clinical trials in Ovarian cancer (Late-stage disease, Metastatic disease, Recurrent, In children, In adults, In the elderly) in USA (IV) (NCT06276491)
- 04 Apr 2024 Phase-I clinical trials in Ovarian cancer (Late-stage disease, Metastatic disease, Recurrent, In children, In adults, In the elderly) in USA (SC) (NCT06276491)
- 04 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, In children, In adults, In the elderly) in USA (IV) (NCT06276491)